Wikidata entity: Q65537382
Quantities
| P4135 | maximum age | 65 |
| P2899 | minimum age | 18 |
| P1132 | number of participants | 146 |
| P6099 | clinical trial phase | ... | Q42824827 (phase III clinical trial) | phase III clinical trial |
| P6099 | clinical trial phase | ... | Q42824440 (phase II clinical trial) | phase II clinical trial |
| P17 | country | ... | Q30 (United States) | United States |
| P31 | instance of | ... | Q30612 (clinical trial) | clinical trial |
| P1050 | medical condition | ... | Q8277 (multiple sclerosis) | multiple sclerosis |
| P1050 | medical condition | ... | Q57859955 (cognitive dysfunction) | cognitive dysfunction |
| P1050 | medical condition | ... | Q140067 (sclerosis) | sclerosis |
| P6153 | research site | ... | Q2725999 (University of Texas Southwestern Medical Center) | University of Texas Southwestern Medical Center |
| P580 | start time | ... | 2004-04-01 | ??? |
| P8363 | study type | ... | Q78089383 (interventional study) | interventional study |
| P1476 | title | Monolingualtext | Double Blind Placebo Controlled Pilot Trial of Memantine for Cognitive Impairment in Multiple Sclerosis | ??? |
| P3098 | ClinicalTrials.gov ID | NCT00300716 |
Why not click here or view trends?
log id: 4905956